Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to
Express News | Chimerix: On June 27, Got Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard From Nasdaq
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patient
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating
Earnings Call Summary | Chimerix(CMRX.US) Q1 2024 Earnings Conference
The following is a summary of the Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript:Financial Performance:The balance sheet at the end of March 2024 reported a $188.2 million available capital wi
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript
Chimerix Releases Updated Corporate Presentation for Investors
Express News | Corrected-Chimerix Q1 Net Income USD -21.9 Million (Corrects Amount)
Express News | Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026
Express News | Chimerix Q1 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate
Express News | Chimerix Inc - Qtrly Net Loss of $21.9 Mln, or $0.25 per Basic and Diluted Share
Press Release: Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update -- Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data
Chimerix 1Q Rev $0.00 >CMRX
Chimerix 1Q Rev $0.00 >CMRX
Express News | Chimerix Q1 Net Income USD -250
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studi
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients